Effectiveness and safety of indobufen in preventing cardiovascular and cerebrovascular events: a Meta-analysis
XU Rong-bin
YANG Jun
HAN Sheng
SUN Feng
MA Jun
Abstract：Objective To review systematically the effectiveness and safety of indobufen in preventing cardiovascular and cerebrovascular events.Methods The databases of CBM, CNKI, WanFang Data, VIP, PubMed, EMbase, Cochrane Library and ClinicalTrail.gov were retrieved with computer for searching the clinical trials or cohort studies on indobufen and control drugs-aspirin or warfarin in preventing cardiovascular and cerebrovascular events from the establishing time of the databases to Oct. 10, 2016. The literature was screened, data was extracted and quality was reviewed by 2 researchers independently and all materials were analyzed by using R 3.3.1 software. Results There were finally 11 RCT and 2 clinical trials with controls included, and 1043 cases in indobufen group and 1040 cases in control group. There were 10 studies with aspirin as control drug, the follow-up time was from 2 w to 6 m, and among them 4 were high-quality studies. There were 3 studies with warfarin as control drug, the follow-up time was 6~12 m, and only 1 was high-quality study. The results of Meta-analysis showed that the differences in all-cause mortality, cardiovascular mortality, stroke, myocardial infarction, pulmonary infarction and whole body infarction had no statistical significance among indobufen, aspirin and warfarin (P>0.05). The adverse events induced by indobufen were less than those induced by aspirin [OR=0.26 (95%CI: 0.16, 0.42)] and warfarin [OR=0.54 (95%CI: 0.32, 0.91)]. The total bleeding events induced by indobufen were less than those induced by aspirin [OR=0.35 (95%CI: 0.17, 0.73)] and warfarin [OR=0.17 (95%CI: 0.07, 0.41)]. The gastrointestinal reactions induced by indobufen were less than those induced by aspirin [OR=0.25 (95%CI: 0.13, 0.49)] and had no statistical significance compared with warfarin (P>0.05). Conclusion The effectiveness of indobufen in preventing cardiac-cerebral vascular events has no difference compared with aspirin and warfarin, while its safety is higher. However, the conclusion should be considered with caution due to the limited quality and quantity of included studies.
Keywords：IndobufenCardiovascular diseasesComparative-effectiveness researchSafetyMeta-analysis
Publication Date：2017-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：7( 532-538 )